Categories for Policy
The Society of Chemical Manufacturers & Affiliates (SOCMA) applauds President Trump’s signing of the United States-Mexico-Canada Agreement (USMCA). The new agreement delivers a substantial win for chemical manufacturing and SOCMA members who have long advocated to update and modernize North American Free Trade Agreement (NAFTA).
January 29, 2020
SOCMA last week advocated for a more practical and representative risk assessment of ethylene oxide (EO) and outlined potential regulatory impacts to batch manufacturers and the specialty chemical value chain during an Environmental Protection Agency (EPA) hearing on proposed amendments to air emissions.
January 21, 2020
Thank you for the opportunity to comment regarding the Office of the U.S. Trade Representative’s (USTR) review of action being taken in the Section 301 investigation involving the enforcement of U.S. World Trade Organization (WTO) rights in the Large Civil Aircraft dispute.
January 13, 2020
SOCMA appreciates the opportunity to submit comments on the Chemical Safety and Hazard Investigation Board’s proposed accidental release reporting rule.
January 13, 2020
SOCMA acknowledges and is grateful for EPA’s ongoing work to resolve the backlog of new chemical notices, to streamline the review process for submissions, and to adopt more realistic assumptions about workplace protections. However, we continue to hear from our members that the current program still lacks predictability and transparency.
December 10, 2019
The Society of Chemical Manufacturers & Affiliates (SOCMA) commends the U.S. Environmental Protection Agency (EPA) on its completion of the Risk Management Plan (RMP) reconsideration rulemaking that was released earlier today.
November 21, 2019
The state of play has reached a critical juncture in U.S.-Mexico-Canada Agreement (USMCA) negotiations (USMCA being the trade agreement that is set to replace NAFTA) as House Democrats continue to work through the thorniest outstanding issues, such as the pact’s labor standards and enforcement mechanism, with the Office of the U.S. Trade Representative.
November 13, 2019
Edward Price, President & CEO, SEQENS N.A. and member of the Bulk Pharmaceuticals Task Force, an affiliate of SOCMA testified to the Subcommittee on Health of the Committee on Energy and Commerce on October 30.
October 30, 2019
Edward Price, President and CEO, SEQENS N.A. and a member of SOCMA’s Bulk Pharmaceutical Task Force, today called for reasonable regulations and increased collaboration between stakeholders during testimony before the House Committee on Energy & Commerce hearing on Pharmaceutical Supply Chains in a Global Economy.
October 30, 2019
Rigid purity and performance demands, costly infrastructure and expertise and economic and global trends often result in a lack of suppliers outside China. And, in the event that alternate sources exist, supplier(s) often lack adequate volume to make up for shortfalls from China and so SOCMA members are placed on insufficient allocation and face price increases that results in the loss of market share to foreign competitors not subject to such taxes on inputs needed to formulate products.
October 17, 2019
